Skip to main content

Brain and CNS.

87 studies recruiting right now, most recently updated first.

Open the Phase 2 page · a list of only those studies

Triangle is made by Triangle Health, Inc.

Brain and CNS87 studies

EGFR-Altered IDH-Wildtype Glioblastoma or GliosarcomaPhase 1NCT07089641

EGFR Inhibitor ERAS-801

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

Jonsson Comprehensive Cancer CenterOpen the brief

Currently Only Enrolling Glioblastoma Patients at First RecurrencePhase 1NCT05139056

Neural Stem Cells-expressing CRAd-S-pk7

Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas

City of Hope Medical CenterOpen the brief

Neoplasms, BrainPhase 1NCT03911388Papers

G207

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

M.D. Anderson Cancer CenterOpen the brief

Recurrent GlioblastomaPhase 1NCT07579208

NK Cells

Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma

M.D. Anderson Cancer CenterOpen the brief

Low Grade Glioma of BrainPhase 1NCT05609994

PEPIDH1M vaccine + vorasidenib

ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas

Katy Peters, MD, PhDOpen the brief

Clinical trials: Phase 1 and Phase 2, explained